The study, published in the journal Alzheimer's & Dementia: The Journal of the Alzheimer’s Association, suggests T2D patients taking semaglutide had a significantly lower risk of developing Alzheimer’s disease. These results were consistent across different subgroups, including obesity status, gender and age.

Semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that decreases hunger and helps regulate blood sugar in T2D, is also the active component in the diabetes and weight-loss drugs Wegovy and Ozempic.

The research team, led by biomedical informatics professor Rong Xu, analysed three years of electronic records of nearly 1 million U.S. patients with T2D. The researchers used a statistical approach that mimics a randomised clinical trial.

They found patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease, compared to those who had taken any of seven other anti-diabetic medications, including other types of GLP-1R-targeting medications.

“This new study provides real-world evidence for its impact on Alzheimer’s disease, even though preclinical research has suggested that semaglutide may protect against neurodegeneration and neuroinflammation,” said Xu, who also directs the medical school’s Centre for AI in Drug Discovery and is a member of the Cancer Genomics Epigenomics Programme at the Case Cancer Comprehensive Centre.

Although their findings potentially support the idea that semaglutide could prevent Alzheimer’s disease, the study’s limitations restrict the researchers from making firm causal conclusions, she said.

“Our results indicate that further research into semaglutide’s use will need to be further investigated through randomised clinical trials so alternative drugs can be tested as potential treatment for this debilitating illness,” Xu said.